Pioneering technologies that create novel antibody therapeutics to treat cancer and other serious diseases.
Research
Innovation
Discover how ÐǺ£ÆåÅÆ makes a positive impact for patients, communities, employees and the environment
Corporate and financial resources for ÐǺ£ÆåÅÆ investors, potential shareholders and analysts
Resources
Financials
Stock Information
Governance
Annual Report 24
Annual Report Overview 2024
By 2030, our knock-your-socks-off (KYSO®) antibody medicines are fundamentally transforming the lives of people with cancer and other serious diseases.
Chair’s Statement
For 25 years, ÐǺ£ÆåÅÆ has pioneered antibody-based medicines to fundamentally transform the lives of people with cancer and other serious diseases.
Deirdre P. Connelly
Board Chair
Read the Chairman’s statement
2024 at a Glance
We have focused our attention to the present, and our eyes to the future; a future in which our KYSO antibody medicines can fundamentally transform the lives of patients for the better.
Key Stats
99BDKK
2024 year-end market cap
21,526MDKK
2024 revenue
13,538MDKK
2024 operating expenses, 72% invested in R&D
Operating Profit*
6,703DKK million
5,321 (2023)
6,267 (2022)
2,953 (2021)
6,290 (2020)*
*2020 Operating Profit impacted by one-time AbbVie upfront payment.
Liquidity and Capital Resources
11,243MDKK
Marketable securities
9,858MDKK
Cash and cash equivalents
36,697MDKK
Shareholders’ equity
A message from our CEO & CFO
“
As I reflect on 2024, I am proud to share a year of remarkable progress and strategic achievement at ÐǺ£ÆåÅÆ. This year has reinforced our commitment to transforming the lives of people with cancer and other serious diseases through groundbreaking antibody-based medicines.
Jan G. J. van deWinkel, Ph.D.
President & CEO
“
We are increasingly prioritizing investment into programs that have a clear line of sight to generate meaningful revenue, especially our Phase 3 programs, EPKINLY, Rina-S and acasunlimab. In order to be well positioned at the end of this decade, these are the investments that we need to make today.
AnthonyPagano
Executive Vice President & Chief Financial Officer
Key downloads
2024 Annual Report
Corporate Governance 2024
Compensation Report 2024
Key highlights from 2024
We are experts in antibody discovery and development. Our appreciation for, and understanding of, the power of the human immune system gives us a unique perspective on how to respond to the constant challenges of oncology drug development.
We are committed to being a sustainable, socially responsible biotech company. This commitment is anchored in our vision, core purpose and values, focused for impact through our CSR strategy, and lived every day by our team. It is fundamental to the way we do business.
Our pipeline of antibody therapeutics includes investigational medicines in clinical development, and in-house and partnered pre-clinical programs.
Press contacts
Reach out to the ÐǺ£ÆåÅÆ team for more information.
Andrew Carlsen
Vice President, Head of Investor Relations
For general Investor Relations Inquiries please contact ir@genmab.com.
